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a b s t r a c t
The adenovirus E4orf4 protein regulates the switch from early to late gene expression during the adenoviral
replication cycle. Here we report that overexpression of adenovirus E4orf4 induces human papillomavirus
type 16 (HPV-16) late gene expression from subgenomic expression plasmids. E4orf4 speciﬁcally overcomes
the negative effects of two splicing silencers at the two late HPV-16 splice sites SD3632 and SA5639. This
results in the production of HPV-16 spliced L1 mRNAs. We show that the interaction of E4orf4 with protein
phosphatase 2A (PP2A) is necessary for induction of HPV-16 late gene expression. Also an E4orf4 mutant that
fails to bind the cellular splicing factor ASF/SF2 fails to induce L1 mRNA production. Collectively, these results
suggest that dephosphorylation of SR proteins by E4orf4 activates HPV-16 late gene expression. Indeed, a
mutant ASF/SF2 protein in which the RS-domain had been deleted could itself induce HPV-16 late gene
expression, whereas wild type ASF/SF2 could not.
© 2008 Elsevier Inc. All rights reserved.

Introduction
Human papillomavirus (HPV) type 16 is the most common cancerassociated HPV type in the human population. In rare cases, HPV-16
infections are not cleared by the immune system and persist for
decades. Persistent HPV-16 infections constitute a risk factor for
development of cervical cancer (zur Hausen, 2002). Progression to
cancer requires expression of viral early gene products E6 and E7 to
drive cell proliferation (Howley and Lowy, 2001). Expression of HPV-16
L1 and L2 is rarely, if ever, seen in mitotic cells in pre-malignant lesions
or cervical cancer (Doorbar, 2005). Based on the well-established
observation that HPV-16 late gene expression is cell-differentiationdependent, we speculate that inhibition of the highly immunogenic L1
and L2 capsid proteins is a prerequisite for progression to cancer.
Papillomaviruses produce a large number of alternatively spliced
mRNAs (Baker and Calef,1997). At the RNA level, regulatory RNA elements,
and the factors they interact with, must be present on the viral genome to
prevent usage of late splice sites or polyadenylation signals at an early
stage of the viral replication cycle (Mole et al., 2006; Schwartz, 2008;
Schwartz et al., 2007; Zheng and Baker, 2006). On the other hand, other
regulatory RNA elements are probably needed to induce late gene
expression at the appropriate time during a productive HPV-16 infection
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(Mole et al., 2006; Schwartz, 2008; Schwartz et al., 2007; Zheng and Baker,
2006). Previously published results from several groups have identiﬁed
cis-acting regulatory RNA elements on HPV mRNAs that affect HPV mRNA
stability (Kennedy et al., 1991; Sokolowski et al., 1997, 1998), polyadenylation (Öberg et al., 2005; Terhune et al., 1999, 2001; Zhao et al., 2005),
splicing (Rush et al., 2005; Zhao et al., 2004, 2007; Zheng et al., 2004) and
translation (Collier et al., 1998; Gu et al., 2004; Wiklund et al., 2002).
Regulatory bovine papillomavirus RNA elements have also been identiﬁed
and characterised (Baker, 1997; Zheng and Baker, 2006). Mutational
inactivation of regulatory RNA elements in the HPV-16 late coding regions
increased L1 and L2 gene expression levels (Collier et al., 2002; Öberg et al.,
2003) to the extent that cellular and humoral immune responses were
induced upon DNA immunisations of mice with these genes (Rollman
et al., 2004). The increase in L1 and L2 expression correlated with less
efﬁcient binding of cellular proteins to the HPV-16 L1 and L2 mRNAs (Zhao
and Schwartz, 2008). Although many cellular factors that bind to HPV and
BPV mRNAs have been identiﬁed (Zhao and Schwartz, 2008), only
polypyrimidine tract binding protein (PTB)/heterologous nuclear ribonucleoprotein I (hnRNP I) has been shown to induce HPV-16 late gene
expression in human cells (Somberg et al., 2008).
Adenoviruses are bigger and more complex DNA viruses than the
HPVs. Similarly to HPV, the replication cycle of adenoviruses is divided
into an early and a late phase. Adenoviral genes are also expressed
from a large number of alternatively spliced mRNAs and regulated
alternative splicing is an essential step in the switch from early to late
gene expression (Akusjärvi and Stevenin, 2003). Adenoviruses encode
two viral proteins named E4orf4 and L4-33K that regulate adenovirus
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alternative splicing and that are key players in the induction of late
gene expression during an adenovirus infection. While L4-33K
appears to have properties similar to cellular splicing factors termed
SR-proteins, and seems to be directly involved in splicing regulation
(Törmänen et al., 2006), E4orf4 is indirectly involved in splicing
regulation due to its ability to bind SR-proteins and PP2A, thereby
altering the function of SR-proteins through dephosphorylation
(Kanopka et al., 1996, 1998). Here we have investigated if the two
key inducers of adenovirus late gene expression E4orf4 and L4-33K
can also induce HPV-16 late gene expression.
Results
Adenoviral protein E4orf4 but not L4-33K, induces HPV-16 late gene
expression
Adenoviral protein E4orf4 (AdE4orf4) is involved in many
important steps in the adenoviral life cycle, including the switch
from early to late gene expression. At the molecular level it induces
apoptosis and has been shown to dephosphorylate SR-proteins by
binding to PP2A (Kanopka et al., 1996, 1998). L4-33K is an adenoviral
protein which functions as a virus-encoded splicing factor that
speciﬁcally activates weak late adenoviral splice sites and induces
early to late switch in adenovirus splicing (Törmänen et al., 2006). In
order to investigate if these viral factors can activate HPV-16 late gene
expression, we are using subgenomic HPV-16 plasmids named pBEL
and pBELM (Fig. 1A) (Zhao et al., 2004), which encode viral early and
late genes after a human cytomegalovirus immediate early (CMV)
promoter placed at the position of the late HPV-16 promoter p670.
These plasmids produce primarily HPV-16 early E4 mRNAs upon
transfection of cervical cancer cells (Zhao et al., 2004) (see Fig. 1G
below). The mutant version of pBEL, named pBELM, also produces low
levels of L1 mRNAs as a result of the mutationally inactivated splicing
silencers in the L1 region (Fig. 1A) (Zhao et al., 2004). Both pBEL and
pBELM are used as reporter plasmids. Overexpression of AdE4orf4
induces HPV-16 late gene expression from pBEL and pBELM, whereas
L4-33K does not (Figs. 1B and C).
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enhanced the production of L1 mRNAs, which contain the middle exon
derived from the HPV-16 E4 coding region, while L1i mRNA levels
were reduced (Fig. 1D). These results suggested that AdE4orf4 acts on
SA3358 and/or SD3632 (Fig. 1A) or sequences in the exon located
between these two splice sites.
A comparison of the late mRNAs that were induced from pBEL and
pBELM, established that AdE4orf4 induces splicing of the late mRNAs,
irrespectively of the absence or presence of splicing silencers in the L1
coding region (Fig. 1E). Induction of spliced L1 mRNA from pBEL by
AdE4orf4 is in sharp contrast to the induction of L2/L1 mRNA by
overexpression of PTB that we have reported previously (Fig. 1F)
(Somberg et al., 2008). While PTB can only overcome the effect of
splicing inhibitory sequences at SD3632, AdE4orf4 overcomes the
effect of splicing inhibitory elements located both at SD3632 and in
the HPV-16 L1 coding region downstream of SA5639 and therefore
induces production of spliced L1 mRNA. Clearly, adenovirus E4orf4
and PTB induce HPV-16 late gene expression by different mechanisms.
Analysis of Northern blots with HPV-16 E4 probe revealed that L1
mRNAs were induced 39-fold from pBELM, while early HPV-16 E4
mRNA levels were reduced only 1.6-fold (Fig. 1G). The small inhibitory
effect on HPV-16 E4 mRNA could be a direct effect of AdE4orf4 on early
mRNA splicing, or an indirect effect of increasing late mRNA splicing.
To distinguish between the two, we cotransfected AdE4orf4 with
pBEarly (Fig. 1A) (Zhao et al., 2005), which expresses only the early
region of the HPV-16 genome and monitored E4 mRNA levels
produced by pBEarly (Fig. 1H). AdE4orf4 did not affect HPV-16 early
mRNAs directly. We also tested AdE4orf4 on plasmid pC97EL (Fig. 2A)
(Somberg et al., 2008), which encodes the entire early region
including E6 and E7 genes, to investigate if AdE4orf4 affected any of
the early mRNAs encoding E6 and E7. Analysis of the early mRNAs in
the absence or presence of AdE4orf4 did not reveal any qualitative or
quantitative differences for any of the detectable early mRNAs (Fig.
2B). Late L1 mRNAs were induced from pC97EL in the presence of
AdE4orf4, as expected (Fig. 2B). Therefore, the reduction of E4 mRNA
levels from pBELM by AdE4orf4 is probably an indirect effect of the
induction of late mRNA splicing by AdE4orf4. Taken together, our
results demonstrate that overexpression of AdE4orf4 speciﬁcally
induces HPV-16 L1 mRNA production.

AdE4orf4 counteracts splicing silencers in the HPV-16 L1 coding region
AdE4orf4 enhances splicing from HPV-16 late splice site SD3632
Cotransfection of AdE4orf4 with pBEL showed, that AdE4orf4
induces mainly the spliced L1 mRNA in a dose dependent manner (Fig.
1C). Similar results were obtained with HPV-negative cell lines C33A
and A459 (data not shown). Cloning and sequencing of RT-PCR
products from this experiment (Fig. 1D) revealed a splicing pattern
consistent with induction of L1 mRNA spliced from SD880 to SA3358
and further from SD3632 to SA5639 (Fig. 1A). Analysis of L1 mRNA
production over a wider mRNA concentration range using real-time
PCR allowed detection of both L1 and L1i mRNAs (Fig. 1A). Real-time
PCR gave rise to two peaks representing the two differently spliced L1
mRNAs. Quantitation of L1 and L1i mRNAs produced from pBEL and
pBELM in the absence or presence of AdE4orf4 revealed that AdE4orf4

To conﬁrm that AdE4orf4 acts directly on HPV-16 late mRNA
splicing, a plasmid that contains only late HPV-16 splice sites (SD3632
and SA5639) was used. This plasmid is named pBSplice (Fig. 3A)
(Somberg et al., 2008). Cotransfection of E4orf4 with pBSplice, or
pBSpliceM (Somberg et al., 2008) in which silencers in L1 have been
inactivated, revealed that spliced L1 mRNAs were induced by E4orf4 in
both cases, although higher levels of L1 mRNAs were obtained from
pBSpliceM than from pBSplice (Fig. 3B). These results conﬁrmed that
AdE4orf4 acts on late HPV-16 splice sites and that it overcomes the
effect of previously described splicing silencer sequences (Rush et al.,
2005; Zhao et al., 2004, 2007).

Fig. 1. (A) Schematic representation of the HPV-16 genome and CMV-promoter driven subgenomic HPV-16 expression plasmids pBEL, pBELM and pBEarly (Zhao et al., 2004, 2005).
Numbers indicate nucleotide positions of 5′-splice sites (ﬁlled circles) and 3′-splice sites (open circles) or early and late polyA signals (pAE and pAL). p97 and p670 indicate early and
late promoters, respectively. Major mRNAs that could be produced by pBEL and/or pBELM are indicated below plasmids. Grey bars represent RT-PCR primers and black bars represent
E4 and L1 probes used for Northern blotting. (B) Northern blot of cytoplasmic RNA extracted from HeLa cells transfected with pBELM in the absence or presence of plasmids
expressing adenovirus E4orf4 (AdE4orf4) or adenovirus L4-33K. The blot was probed with L1 probe and the position of the L1 mRNA is indicated. (C) Northern blot of cytoplasmic RNA
extracted from HeLa cells transfected with pBEL in the absence or presence of increasing concentration of plasmid expressing AdE4orf4. The blot was probed with L1 probe that
detects both L2/L1 and L1 mRNAs. (D) (left panel) RT-PCR on cytoplasmic RNA extracted from HeLa cells transfected with pBEL in the absence or presence of plasmid expressing
AdE4orf4. The RT-PCR was performed either with primer combinations 3515s and L1a, or 757s and L1a (panel A) (Zhao et al., 2005). (right panel) Real time PCR on cytoplasmic RNA
with primers 757s and L1a over a range that detects both L1 and L1i mRNAs as separate peaks. The areas under the peaks are shown as percentage of total and indicate that AdE4orf4
promotes splicing of L1 mRNA, whereas L1i mRNA production is inhibited. (E) Northern blot of cytoplasmic RNA extracted from HeLa cells transfected with pBEL or pBELM in the
absence or presence of plasmids expressing AdE4orf4. Blot was probed with L1 probe and L2/L1 and L1 mRNAs are indicated. (F) Northern blot of cytoplasmic RNA extracted from
HeLa cells transfected with pBEL in the absence or presence of plasmids expressing PTB. Triplicate experiments are shown. Blot was probed with L1 probe and L2/L1 mRNA is
indicated. (G, H) Northern blots of cytoplasmic RNA extracted from HeLa cells transfected with pBELM or pBEarly in the absence or presence of AdE4orf4. Blots were probed with E4
probe and E4 and L1 mRNAs are indicated. Gels were also probed for GAPDH.
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Fig. 2. (A) Schematic representation of subgenomic HPV-16 expression plasmid pC97EL (Somberg et al., 2008). Numbers indicate nucleotide positions of 5′-splice sites (ﬁlled circles),
3′-splice sites (open circles), or polyA sites (pAE and pAL). Major mRNAs produced by pC97EL are indicated below plasmid. Grey bars represent RT-PCR primers. Major mRNAs are
indicated. (B) RT-PCR of cytoplasmic RNA extracted from HeLa cells transfected with pC97EL in the absence or presence of plasmids expressing AdE4orf4. The RT-PCR was performed
with different primer-combinations p97s and E4a (early mRNAs), p97s and 3515a (early mRNAs) and p97s and L1a (late mRNAs) (Table 1). The structures of the detected mRNAs are
shown on each side of the gel. RT-PCR for GAPDH was also performed.

To provide evidence that AdE4orf4 acts on other sequences than
the silencers in the L1 coding region, we tested AdE4orf4 on plasmid
pBSpMDL1 (Fig. 3A). In this plasmid, splicing silencers in L1 that are
located between nucleotide positions 5639 and 6152 (Zhao et al.,
2004) are destroyed by point mutations, and wt L1 sequences with
splicing inhibitory functions located downstream of position 6152
(Zhao et al., 2007) are deleted. Therefore, all previously identiﬁed
splicing silencers in L1 were either deleted or destroyed. Late gene

expression from this plasmid is therefore primarily inhibited by
splicing silencers at the 5-splice site SD3632. Since AdE4orf4 induced
production of spliced L1 mRNAs from pBSpMDL1 (Fig. 3C), we
concluded that AdE4orf4 activates splicing from SD3632.
To conﬁrm that AdE4orf4 acts speciﬁcally on SD3632, we also
tested pBELM-derived plasmids pT1, pT3 and pT4 (Fig. 4A), in which a
key regulatory splicing enhancer (Rush et al., 2005) located downstream of SA3358 in the early region had been deleted. Since splicing

Fig. 3. (A) Schematic representation of the HPV-16 genome and CMV-promoter driven subgenomic HPV-16 expression plasmids. Numbers indicate nucleotide positions of 5′-splice
sites (ﬁlled circles) and 3′-splice sites (open circles) or early and late polyA signals (pAE and pAL). p97 and p67 indicate early and late promoters, respectively. Major potential mRNAs
produced by these plasmids are indicated below pBSpliceM. The E4⁎ mRNA indicates a short mRNA encoding E4 and E5 that is unspliced due to the absence of SD880 and other
5′-splice sites upstream of the major E4 3′-splice site SA3358 in the pBSplice-derived plasmids. The L1 probe used for Northern blotting is indicated. (B, C) Northern blot of
cytoplasmic RNA extracted from HeLa cells transfected with pBSplice, pBSpliceM or pBSpMDL1 in the absence or presence of plasmid expressing AdE4orf4. Blots were probed with L1
probe and L2/L1 and L1 mRNA is indicated. Duplicates are shown in panel C. Gels were also probed for GAPDH.
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Fig. 4. (A) Schematic representation of subgenomic HPV-16 expression plasmid pBELM, pT1 and pT4 (Rush et al., 2005; Zhao et al., 2004). Numbers indicate nucleotide positions of
5′-splice sites (ﬁlled circles) and 3′-splice sites (open circles) or early and late polyA signals (pAE and pAL). p97 and p67 indicate early and late promoters, respectively. Mut indicates
the presence of the L1 mutant sequence in which splicing silencers in L1 had been inactivated by multiple substitutions. The deletions present in the pT1 and pT4 plasmids are
indicated. The major splicing enhancer located in the E4 coding region is indicated (Rush et al., 2005). Major potential mRNAs produced by these plasmids are indicated. The L1 probe
used for Northern blotting is indicated. (B) Northern blot of cytoplasmic RNA extracted from HeLa cells transfected with pBELM, pT1 or pT4 in the absence or presence of plasmid
expressing AdE4orf4. Blot was probed with L1 probe and L2/L1, L1 and L1i mRNAs are indicated and with GAPDH probe.

silencers in L1 had been inactivated by mutations as well, splicing
occurs directly from SD880 to SA5639, thereby bypassing the central
exon using SA3358–SD3632 (Rush et al., 2005). pT1 and pT4 produce
primarily spliced L1i mRNA (Figs. 4A and B). Overexpression of
AdE4orf4 did not increase L1 mRNA levels further (Fig. 4B). In contrast,
AdE4orf4 induced expression of L1 mRNA from pBELM, as expected
(Fig. 4B). RT-PCR results conﬁrmed that SD880, and not SD3632, is
used in pT1 and pT4 (data not shown). These results conﬁrmed that
AdE4orf4 acts speciﬁcally on the suppressed SD3632, and not on

SD880. Taken together, our results demonstrate that AdE4orf4 induces
splicing from the suppressed splices sites SD3632 and SA5639 that are
used exclusively by late HPV-16 mRNAs.
Novel late mRNA splicing-enhancing sequence in HPV-16 L2 is needed for
induction of L1 mRNA by PTB, but not by AdE4orf4
In an effort to map the target sequence for AdE4orf4, we ﬁrst
introduced deletions from nucleotide position 4288 in L2 to various

Fig. 5. (A) Schematic representation of subgenomic HPV-16 expression plasmids pBSpliceM, pBSpM4288–4530, pBSpM4288–5150 and pBSpM4288–5505. Numbers indicate
nucleotide positions of 5′-splice sites (ﬁlled circles) and 3′-splice sites (open circles), positions of pAE and pAL mark the borders of deletions. Major mRNAs produced by these
plasmids are indicated. The E4⁎ mRNA indicates a short mRNA encoding E4 and E5 that is unspliced due to the absence of SD880 and other 5′-splice sites upstream of the major E4
3′-splice site SA3358 in the pBSplice-derived plasmids. The L1 probe used for Northern blotting is indicated. Northern blots of cytoplasmic RNA extracted from HeLa cells transfected
with indicated HPV-plasmids in the absence or presence of plasmid expressing AdE4orf4 (B) or PTB (C). Blots were probed with L1 probe and L2/L1 and L1 mRNAs are indicated. Gels
were also probed for GAPDH.
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positions further down in L2 in pBSpliceM (Fig. 5A). The results
revealed that AdE4orf4 induced production of spliced L1 mRNA to a
similar extent in all deletions, including pBSpMD4288–5505 in which
1218 nucleotides of the 1422 nucleotides of L2 had been deleted (Fig.
5B), indicating that AdE4orf4 acts independently of L2 sequences.
Interestingly, the PTB protein that only induces spliced L1 mRNA if L1
silencers are destroyed, only induced L1 mRNA from the smallest L2deletion (pBSpMD4288–4530). In contrast, only unspliced late mRNAs
were induced from the larger L2 deletions by PTB (Fig. 5C). That these
slower migrating bands represented unspliced mRNAs was conﬁrmed
by RT-PCR (data not shown). These results indicated that induction of
spliced L1 mRNA by PTB is dependent on a sequence located
downstream of nucleotide position 4530 in the HPV-16 L2 coding
region (Fig. 5A). This region may therefore encode a conditional,
splicing enhancer element. Since AdE4orf4 acted independently of
this sequence, the simplest explanation is that AdE4orf4 counteracts
the effect of multiple inhibitory RNA elements and therefore is
independent of splicing enhancers in L2. These results further
supported the conclusion that PTB and AdE4orf4 induce HPV-16 late
gene expression by different mechanisms. We concluded that
AdE4orf4 induces late mRNA splicing independently of sequences in
the HPV-16 L2 coding region, whereas PTB does not.

AdE4orf4 alleviates inhibition from splicing silencer elements downstream
of HPV-16 late splice site SD3632
To map the AdE4orf4 target sequences at SD3632, the effect of
AdE4orf4 on plasmids with various deletions at SD3632 were
analysed. The deletion mutants are shown in Fig. 6A. Both pMT2
and pMT22 produced high levels of L1 mRNA, both in the absence and
presence of AdE4orf4, indicating that splicing silencer elements had
been deleted (Figs. 6B and C). Note that SD3632 is also deleted in
plasmid pMT22 and that a previously described cryptic splice donor
CSD4313 is used in this plasmid (Somberg et al., 2008 and data not
shown). Two non-overlapping deletions were introduced between
SD3632 and pAE, resulting in pMT3 and pMTD198 (Fig. 6A). AdE4orf4
induced late mRNAs from both plasmids (Fig. 6B), suggesting that
there are two splicing inhibitory elements between SD3632 and pAE.
A series of deletions (pMT31, -32 and -33 (Fig. 6A)) were analysed and
were all found to be responsive to AdE4orf4 (Fig. 6C). Therefore, one
splicing inhibitory element is located between SD3632 and 3700.
Alternatively, the early polyA signal (pAE) that competes with
SD3632, also directly suppresses SD3632. We therefore extended the
deletion in pMT3 to include also pAE, resulting in pMTDpAE (Fig. 6A).
L1 mRNA production from this plasmid is suppressed in the absence of

Fig. 6. (A) Schematic representation of subgenomic HPV-16 expression plasmids pBSpliceM and pBSpliceM-derived deletion mutants. Numbers indicate nucleotide positions of 5′splice sites (ﬁlled circles) and 3′-splice sites (open circles), positions of pAE, pAL and cryptic 5′-splice site (CSD) mark the borders of deletions. Major mRNAs produced by these
plasmids are indicated below the plasmids. The E4⁎ mRNA indicates a short mRNA encoding E4 and E5 that is unspliced due to the absence of SD880 and other 5′-splice sites
upstream of the major E4 3′-splice site SA3358 in the pBSplice-derived plasmids. The L1 probe used for Northern blotting is indicated. (B, C, D and E) Northern blots of cytoplasmic
RNA extracted from HeLa cells transfected with indicated plasmids in the absence or presence of AdE4orf4. Blots were probed with L1 probe and L1 mRNAs are indicated. Gels were
also probed for GAPDH.
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AdE4orf4 (Fig. 6D), but is induced by AdE4orf4. These results suggest
that pAE per se is not needed for inhibition of late gene expression.
However, we cannot exclude that a cryptic polyA signal at nucleotide
position 3820, previously named CpA (Zhao et al., 2005), suppresses
late gene expression in pMTDpAE. Cryptic polyA signals are activated
upon inactivation of pAE also in BPV-1 (Andrew and DiMaio, 1993) and
HPV-31 (Terhune et al., 1999, 2001). We concluded that AdE4orf4
activates the suppressed late splice site SD3632 by overcoming the
effect of adjacent splicing inhibitory elements.
To further investigate if pAE was speciﬁcally targeted by AdE4orf4
and was required for AdE4orf4-mediated induction of HPV-16 late
gene expression, we analysed the effect of AdE4orf4 on pBELDP (Fig.
7A) (Zhao et al., 2005), a plasmid in which the pAE had been
mutationally inactivated by point mutations in the canonical AAUAAA
motif, converting it to an MluI site (ACGCGU) (Zhao et al., 2005).
However, AdE4orf4 efﬁciently induced late gene expression from
pBELDP (Fig. 7B), demonstrating that pAE was not required for
induction of HPV-16 late gene expression by AdE4orf4.
To conﬁrm that pAE was not targeted by AdE4orf4, we replaced
pAE by the HPV-16 late polyadenylation signal pAL in pBspliceM
(plasmid p2pAL (Fig. 7A) (Somberg et al., 2008)). pAL is not negatively
affected by AdE4orf4 since it is used efﬁciently by the HPV-16 L1
mRNAs that are induced by AdE4orf4. AdE4orf4 induced high levels of
late mRNAs from plasmid p2xpAL that carries two late polyA signals
(Fig. 7C). We concluded that AdE4orf4 does not induce HPV-16 late
gene expression by speciﬁcally inhibiting the early polyA signal.
Further experiments are needed to establish the exact mechanism of
suppression of SD3632 in the absence of AdE4orf4.
Overexpression of proapoptotic proteins Bad, Bax and p53 or APC/C
inhibitor Emi-1 does not induce HPV-16 late gene expression
One of the most characteristic properties of AdE4orf4 is its ability to
induce apoptosis (Branton and Roopchand, 2001; Kleinberger, 2000).
During the HPV-16 life cycle, the late genes are expressed in fully
differentiated epithelial cells. Induction of HPV-16 late genes by AdE4orf4
could therefore be a response to induction of apoptosis. In addition, p53
has been shown to enhance adenovirus late gene expression (Royds et al.,
2006). We therefore tested if proapoptotic proteins p53, Bad and Bax
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could induce HPV-16 late gene expression, but none of these proteins did
(Figs. 8A–C). The results were conﬁrmed in HPV negative cell lines (data
not shown). In addition anti apoptotic protein Bcl-2 could neither induce
HPV-16 late gene expression, nor counteract the effect of AdE4orf4
(Fig. 8D). We concluded that HPV-16 late gene expression could not be
induced by these regulators of apoptosis.
Adenovirus E4orf4 can induce apoptosis in a p53-independent
manner, by inhibiting the anaphase promoting complex APC/C through
dephosphorylation (Kornitzer et al., 2001). In uninfected cells, the APC/
C is instead regulated by the cellular Emi-1 protein, which also inhibits
APC/C through dephosphorylation (Reimann et al., 2001). The viral
HIV-1 vpr protein also induces apoptosis and interferes with G2/M
control (Stewart et al., 1999), but through another mechanism than
AdE4orf4. Neither overexpression of Emi-1, nor HIV-1 vpr, induced
HPV-16 late gene expression from pBEL or pBELM (Figs. 8E and F).
Taken together, these results demonstrated that HPV-16 late gene
expression is not induced by proapoptotic factors, nor by inhibition of
the APC/C complex. We concluded that AdE4orf4 induced HPV-16 late
gene expression through another pathway.
Binding of AdE4orf4 to PP2A is necessary for induction of HPV-16 late
gene expression
Interaction of AdE4orf4 with protein phosphatase type 2A (PP2A) is
required for dephosphorylation of APC/C (Kornitzer et al., 2001) or SR
proteins (Kanopka et al.,1996, 1998). HPV-16 E7 and polyomavirus small
t protein also bind PP2A (Pallas et al., 1990; Pim et al., 2005), but they
could not induce HPV-16 late gene expression (Figs. 9A, B and data not
shown). However, when polyomavirus small t is co-expressed with
AdE4orf4, it inhibits AdE4orf4-mediated induction of HPV-16 late gene
expression (Fig. 9B). In contrast, a previously described mutant
polyomavirus small t protein that does not bind to PP2A (Fan, 2001),
had no effect on AdE4orf4-induction of HPV-16 late gene expression
(Fig. 9B). The most likely explanation for these results is that
polyomavirus small t, that binds to the A-subunit of PP2A and displaces
the B-subunit, inhibits AdE4orf4 interaction with PP2A since AdE4orf4 is
known to mediate its effect by interacting with the B-subunit to recruit
PP2A (Branton and Roopchand, 2001; Kleinberger, 2000). Overexpression of polyomavirus small t therefore is highly likely to reduce the

Fig. 7. (A) Schematic representations of subgenomic HPV-16 expression plasmids pBELDP (Zhao et al., 2005) and p2xpAL (Somberg et al., 2008). Numbers indicate nucleotide
positions of 5′-splice sites (ﬁlled circles) and 3′-splice sites (open circles), or pAE and pAL. Crossed pAE indicates that pAE is mutationally inactivated in these plasmids by point
mutations or deletions (Somberg et al., 2008; Zhao et al., 2005). (B, C) Northern blots of cytoplasmic RNA extracted from HeLa cells transfected with pBELDP or p2xpAL in the absence
or presence of AdE4orf4. Duplicates are shown in panel B. Blots were probed with L1 probe and L2/L1 and L1 mRNAs are indicated. Gels were also probed for GAPDH.
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Fig. 8. (A–F) Northern blots of cytoplasmic RNA extracted from HeLa cells transfected with pBEL or pBELM in the absence or presence of plasmids expressing AdE4orf4, p53, Bax, Bad,
Bcl-2, Emi-1 or HIV-1 vpr. Blots were probed with L1 probe and L1 and L2/L1 mRNAs are indicated. Gels were also probed for GAPDH.

Fig. 9. (A–C) Northern blots of cytoplasmic RNA extracted from HeLa cells transfected with pBEL or pBELM in the absence or presence of plasmids expressing AdE4orf4, polyoma small
T-wt (PYsTwt), polyoma small T-mut (PYsTPP2A-) (which fails to bind PP2A) or AdE4orf412 (Shtrichman et al., 1999) (which fails to bind PP2A). Duplicate transfections are shown in
panels A and C. (D) Northern blots of cytoplasmic RNA extracted from HeLa cells transfected with pBELM and AdE4orf4 in the absence or presence of okadaic acid. Blots were probed
with L1 probe and L1 and L2/L1 mRNAs are indicated. Gels were also probed for GAPDH.
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Fig. 10. (A, B) Northern blots of cytoplasmic RNA extracted from HeLa cells transfected with pBELM in the absence or presence of plasmids expressing AdE4orf4, AdE4orf4R2 (which
fails to bind SR-protein ASF/SF2 (Estmer Nilsson et al., 2001), but still interacts with PP2A (Shtrichman et al., 1999)), ASF/SF2 or ASFDRS, a deletion mutant of ASF/SF2 that lacks the RSdomain. Duplicate transfections are shown. Blots were probed with L1 probe and L1 mRNAs are indicated. Gels were also probed for GAPDH.

intracellular pool of PP2A that is available to AdE4orf4. These results are
in line with the hypothesis that binding of AdE4orf4 to PP2A is necessary
for induction of HPV-16 late gene expression.
To conﬁrm that PP2A is needed for induction of HPV-16 late gene
expression by AdE4orf4, we also tested a previously described
AdE4orf4 mutant named E4orf4/R12 (Shtrichman et al., 1999), in
which asparagine at amino acid position #60 had been replaced by
serine, and therefore does not bind PP2A (Shtrichman et al., 1999).
This mutant does not induce HPV-16 late gene expression, as expected
(Fig. 9C). Finally, if PP2A is required for induction of HPV-16 late gene
expression, okadaic acid should inhibit this effect of AdE4orf4, which
is shown in Fig. 9D. We concluded that binding of AdE4orf4 to PP2A is
required for induction of HPV-16 late gene expression by AdE4orf4.
ASF/SF2 lacking RS-domain efﬁciently induces HPV-16 late gene expression
It has previously been shown that AdE4orf4 binds ASF/SF2, and that
it causes dephosphorylation of ASF/SF2 in vitro (Kanopka et al., 1996,
1998). A mutant AdE4orf4 protein that does not bind ASF/SF2 (E4orf4/
R2) (Estmer Nilsson et al., 2001), but still interacts with PP2A (Shtrichman et al., 1999), failed to induce HPV-16 late gene expression (Fig. 10A),
suggesting that binding of AdE4orf4 to ASF/SF2 is required for induction
of HPV-16 late gene expression. We speculated that dephosphorylated
ASF/SF2 could induce HPV-16 late gene expression and tested if
overexpression of AdE4orf4 in HeLa cells caused dephosphorylation of
AFS/SF2. However, we were unable to detect SR protein dephosphorylation in AdE4orf4-transfected cells (data not shown), suggesting that only
a fraction of ASF/SF2 is dephosphorylated in these cells. In an effort to
provide evidence that dephosphorylated ASF/SF2 could induce HPV-16
late gene expression, a mutant ASF/SF2 lacking the RS-domain (ASF/SF2/
DRS) was tested. This mutant ASF/SF2 protein could no longer be
phosphorylated. As can be seen in Fig. 10B, ASF/SF2/DRS, induced high
levels of HPV-16 L1 mRNAs, while wt ASF/SF2 protein did not. Induction
of HPV-16 late gene expression is less efﬁcient with ASF/SF2/DRS than
with AdE4orf4. We concluded that ASF/SF2 induced high levels of HPV16 L1 mRNAs in its unphosphorylated state, independently of the RSdomain. Transfection with a combination of AdE4orf4 and ASF/SF2/DRS
increased L1 mRNA expression further (Fig. 10B), as expected since
AdE4orf4 targets endogenous ASF/SF2. We concluded that ASF/SF2
induces HPV-16 late gene expression only in the absence of RS-domain
phosphorylation, supporting the idea that AdE4orf4 induces HPV-16 late
gene expression by dephosphorylating ASF/SF2.
Discussion
AdE4orf4 apparently overcomes the activity of the splicing
inhibitory sequences at both HPV-16 splice sites SD3632 and
SA5639, which are the only splice sites that are used exclusively by

late HPV-16 mRNAs. Both splice sites are either suppressed by the
same cellular factor(s), or AdE4orf4 interacts with multiple cellular
RNA regulatory proteins. Splicing silencers at SA5639 have been
shown to interact with hnRNP A1 (Zhao et al., 2004, 2007). It remains
to be investigated if AdE4orf4 interferes with the function of hnRNP
A1. AdE4orf4 has been shown to bind ASF/SF2 and it has been shown
to dephosphorylate ASF/SF2 in vitro (Estmer Nilsson et al., 2001;
Kanopka et al., 1998). Here we show that overexpression of a deletion
mutant of ASF/SF2 that cannot be phosphorylated induces HPV-16 late
gene expression. These results support the conclusion that AdE4orf4
acts by targeting ASF/SF2 for dephosphorylation. Overexpression of
ASF/SF2 inhibits adenovirus late gene expression (Molin and Akusjarvi, 2000) and seems to have an inhibitory effect on HPV-16 gene
expression as well (Fig. 10). One may speculate that phosphorylated
ASF/SF2 inhibits HPV-16 late gene expression and that this inhibition
is relieved by overexpression of AdE4orf4 or by deletion of the RSdomain of ASF/SF2, which prevents ASF/SF2 phosphorylation. The
mechanism by which ASF/SF2 regulates HPV-16 late gene expression
is unclear but is under investigation. ASF/SF2 has also been shown to
bind to the late UTR of HPV-16 (McPhillips et al., 2004), but the
presence or absence of the late UTR did not affect the response to ASF/
SF2 in our experiments (data not shown).
The RS domain of ASF/SF2 interacts with U2AF35 (Wu and
Maniatis, 1993), but has also been shown to bind RNA (Hertel and
Graveley, 2005), in both cases to stimulate the splicing reaction.
Overexpression of ASF/SF2 has been shown to inhibit late mRNA
splicing during an adenovirus infection (Molin and Akusjärvi, 2000).
Recent data demonstrate that ASF/SF2 is not simply inhibiting splicing
by competing with another splicing factor, but actively inhibits
splicing (Dauksaite and Akusjärvi, 2002). These results demonstrate
that ASF/SF2 can play the role of either a splicing suppressor or
activator, depending on context.
A comparison with the effect of PTB on HPV-16 late gene
expression revealed that PTB induces expression of L2/L1 mRNAs
(Somberg et al., 2008), unless splicing silencers at SA5639 were
inactivated, demonstrating that PTB overcomes the splicing silencers
at SD3632, but not those at SA5639. In contrast, E4orf4 overcomes the
effect of splicing silencers at both late splice sites. In addition,
induction of late mRNAs by PTB also required splicing enhancing
elements in the L2 coding region, whereas induction of L1 mRNA by
AdE4orf4 occurred independently of these elements. It is therefore
reasonable to speculate that AdE4orf4 targets multiple proteins and
that one of those also interacts with PTB. Proteins interacting with
both AdE4orf4 and PTB have not been identiﬁed. There does not
appear to be PTB binding sites in the splicing silencer at SD3632 and
AdE4orf4 is not an RNA-binding protein, suggesting that both PTB and
AdE4orf4 may target a cellular factor rather than HPV-16 RNA. Both
proteins may interact with ASF/SF2 to prevent ASF/SF2 from inhibiting
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HPV-16 late gene expression. However, ASF/SF2 binding sites cannot
be detected in this region with the increased speciﬁcity score matrix
for prediction of ASF/SF2 binding sites (Cartegni et al., 2003).
Alternatively, PTB and AdE4orf4 simply interact with different
proteins. It will be of interest to identify the cellular factors that
bind to HPV-16 RNA and suppress SD3632.
One draw back with the experimental system used here is that
HeLa cells are unable to differentiate. One can therefore not
investigate the effect of AdE4orf4 on HPV-16 in a differentiating
environment, such as the W12 cell lines, derivatives thereof (Lambert
et al., 2005) or cell lines created by transfection with immortalising
HPV types (Lee et al., 2004; McLaughlin-Drubin and Meyers, 2005). It
would be informative to investigate the status of PTB and ASF/SF2 in
cell lines that are permissive for HPV-16 virus production.
The more sophisticated adenoviruses encode proteins that induce
a shift in viral RNA splicing, thereby initiating the late gene expression
program (Akusjärvi and Stevenin, 2003). HPVs on the other hand, are
less complex and encode relatively few proteins. One may speculate
that HPVs simply sit in the epithelial cells and await terminal cell
differentiation and a change in the intracellular environment that
activates late gene expression. We have shown that SR proteins as a
group are down-regulated in terminally differentiated cells and using
a monospeciﬁc antibody against ASF/SF2 this was shown also for ASF/
SF2 speciﬁcally (Fay et al., in press). We have also shown that SR
proteins are strongly overexpressed in cervical cancers (Fay et al., in
press), which support the recently published results that classify ASF/
SF2 as an oncogene (Karni et al., 2007). The expression pattern of ASF/
SF2 shows an inverse correlation with HPV-16 late gene expression in
the epithelium, indicating that other factors than ASF/SF2 induce HPV16 late gene expression, or that the few cells in the cervical epithelium
that actually express HPV-16 L1 and L2 are also producing unphosphorylated ASF/SF2. Alternatively, the anti-ASF/SF2 antibody used
detects unphosphorylated ASF/SF2 less efﬁciently than phosphorylated ASF/SF2. It would be of interest to determine the role of ASF/SF2
in the HPV-16 life cycle.
Materials and methods
Plasmid constructions
pBEL and pBELM, have been described previously (Zhao et al., 2004).
pT1, pT2, pT3, pT4, pBSplice (pBSplice was referred to as pC16L1L2splice)
and pBSpliceM have been described (Rush et al., 2005). pMT1, pMT2,
pMT3, pMT22, p2xpAL, pC97EL, pBSpMDL1, pBSpMD4288–4530 and
pCMVPTB1 have been described (Somberg et al., 2008). pBearly and
pBELDP have been described previously (Zhao et al., 2005).
pBSpMD4288–5505 was created by ﬁrst PCR amplifying a
sequence from pBR-HPV-16 with oligonucleotides M4S and 16F
(Table 1). The PCR fragment was subcloned into pCR2.1-TOPO,
released with ApaI and BamHI and subcloned into pBSpMD4288–
4530. pBSpMD4288–5150 was created by ﬁrst PCR amplifying a
sequence from pBR-HPV-16 with oligonucleotides M12S and 16F
(Table 1). The PCR fragment was subcloned into pCR2.1-TOPO,
released with ApaI and BamHI and subcloned into pBSpD4288–4530.
pMT31, pMT32 and pMT33 were created by PCR amplifying a
sequence from pBR-HPV-16 with oligonucleotides 3455s and M21A,
M22A and M23A respectively (Table 1). PCR fragments were digested
with XbaI and MluI and cloned into pMT1.
pMT198 was created by PCR amplifying a sequence from pBR-HPV16 with oligonucleotides M14S and M17A (Table 1), PCR fragment was
digested with MluI and ApaI and cloned into pMT2. pMTDpAE was
constructed by cutting of pMT3 with MluI and ApaI followed by ﬁlling
in, trimming and religation.
HIV-1 vpr plasmid referred to as pNL13AE has been described
previously (Schwartz, Felber, and Pavlakis, 1991). pASF/SF2, pASF/
SF2DRS, pL4-33K, pE4orf4, pE4orf4R2 and pE4orf4R12 have been

Table 1
Oligonucleotides
Oligo name

Oligo sequence

M3A
M4S
M12S
M14S
M17A
M21A
M22A
M23A
16F
3455s

GGGCCCAGGCCTCGACACTGCAGTATACAATGTACAATGCT
AGGCCTGGGCCCGCTCCTTCATTAATTCCTATAGTTCCAGGG

AGGCCTGGGCCCAATTGGTAATAAACAAACAC
GGACGCGTATGACAAATCTTGATACTGCATCC
CACTAAAGAAACCTATAGAAGGATCAG
GACGCGTGAGACAAAAATTGGTCACACGTTGCCATT
GACGCGTATTGCACTTTTATGTTTTACATTATGT
GACGCGTCACTGCAGTATACAATGTCAAATGCTT
CCTCGAGCATTTTAATATAATCTGGATATTTGC

GCGCGCTCTAGACCAACCACCCCGCCGCGACC

described previously (Shtrichman et al., 1999; Törmänen et al., 2006).
Plasmids encoding HPV-16 E7, murine polyoma sT (wt (PYsTwt) and
mutant (PYsTPP2A-) (Fan, 2001)), BAX, Bad, Bcl2 and Emi1 under CMV
promoter were generously provided by Drs Lawrence Banks, Göran
Magnusson, Alan Escher, John C. Reed, Strathford May and Peter Jackson,
respectively.
Transfection and cell culture
HeLa cells were cultured in Dulbecco's Modiﬁed Eagle Medium
(DMEM) containing 10% heat inactivated foetal bovine calf serum and
Penicillin–Streptomycin. Transfections were carried out by using
Fugene 6 according to manufacturer's protocol (Roche Molecular
Biochemicals) as described previously (Somberg et al., 2008). All
plasmids were transfected in a minimum of three independent
experiments with similar results.
RNA extraction, Northern blotting and radiolabelled DNA probe synthesis
Cytoplasmic RNA was extracted using NP40 buffer as described
previously. The RNA was treated with DNaseI prior to Northern
blotting. Northern blot analysis was carried out by size separation of
10 μg cytoplasmic RNA on a 1.2% agarose gels containing 2.2 M
formaldehyde. The RNA was transferred over night to a nitrocellulose
ﬁlter followed by hybridization with either L1, E4 or GAPDH probe as
described previously (Somberg et al., 2008; Zhao et al., 2004). L1
probe was excised from pBEL with BamHI and XhoI whereas the E4
probe was generated by PCR using the following primers: E4S and K1.
DNA probes were radiolabelled with [α-32P]dCTP using a Decaprime
kit (Ambion).
Reverse Transcription (RT)-PCR
200 ng of cytoplasmic RNA was reverse transcribed at 42°C using
Superscript II and random hexamers according to the manufacturer's
protocol (Invitrogen). 2 μl of cDNA was ampliﬁed in a 100 μl PCR
reaction using oligonucleotides indicated in the ﬁgures, as described
previously. GAPDH cDNA was ampliﬁed as control using previously
described primers (Somberg et al., 2008).
Real-time PCR
Real-time PCR was carried out on random hexamer primed reverse
transcribed cDNA products using primers GAPDHF (5′-AGGTCGGAGTCAACGGATTTGG-3′) and GAPDHR (5′-ACAGTCTTCTGGGTGGCAGTGATG-3′) or 757s (5′-TCGGTTGTGCGTACAAAGCACACACG-3′) and
L1A-wt (5′- CCGTGCTTACAACCTTAGATACTGGGACAG-3′) or L1A-mut
(5′- AAGCTTGGATCCCGCTGGGCAGCCACAG -3′). All real-time PCRs
were carried out using Lightcycler FastStart DNA Master SYBR Green I
Kit. All real-time PCRs were analysed for speciﬁcity by melt curve
analysis. GAPDH from each individual transfection was used to
normalise the L1 mRNA values for each transfection. Peak area data
was calculated using the Lightcycler 3 software and was used to

M. Somberg et al. / Virology 383 (2009) 279–290

calculate L1 mRNA averages and peak area percentages for graphs and
standard error for error bars.
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